Holiday Inn, Bratislava, Slovakia

11th October 2014

Slovak

5 CME kreditmi

je ubytovanie zabezpečené v mieste konania, hotel Holiday Inn, Bratislava www.holidayinn.sk

• dvojlôžková izba – 99 €

(cena je uvedená s DPH, zahŕňa ubytovanie, raňajky, miestny poplatok 1,65 €)

Ubytovanie je možné rezervovať prostredníctvom organizátora podujatia písomnou formou – prihláška na ubytovanie je súčasťou prihlášky na účasť a registračného formulára.

Rezervácia je záväzná, zmena bola možná bez účtovania storno poplatku do 19. 9. 2014.

Po tomto termíne sa o možnostiach ubytovania informujte u organizátora.

Odborný program

8.00 - 8.30 Registration

8.30 - 8.35 Welcome

President of Slovak Oncology Society, Jozef Mardiak

I. Genitourinary and Gynecologic Cancer & Sarcoma Session

Chairmen: Igor Andrašina, Jozef Mardiak (8.35 - 9.35)

08.35 - 08.55

1.Genitourinary Cancer (Jana Obertova, NOU Bratislava)

1. Abstract # LBA2 (127755) Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. (Christopher Sweeney)
2. Abstract # 5003 (131550) Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. (Xabier Garcia-Albeniz)
3. Abstract # 5001 Androgen Receptor Splice Variant-7 (AR-V7) and Resistance to Enzalutamide and Abiraterone in Men with Metastatic Castration-Resistant Prostate Cancer. (E. S. Antonarakis)
4. Abstract # 5008 (126204) Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-nai.ve metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial). (Ronald De Wit)
5. Abstract # 4500 (130351) Final results of EORTC intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder. (Cora N. Sternberg)
6. Abstract # 5011 (128960) Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). (Thomas Powles)
7. Abstract # 5009 (125893) Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial. (Robert J. Motzer)
8. Abstract # 4505 (134866) Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial. (Nizar M. Tannir)
9. Abstract # 5012 (125914) Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. (Toni K. Choueiri)

8.55 - 09.15

2. Gynecologic Cancer/Sarcoma (Jozef Šufliarsky, NOU Bratislava)

3. Abstract #5508 (133296) Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in phase III randomized trial: JCOG0602. (Takashi Onda)

4. Abstract #5507 (132845) Randomized phase III trial of paclitaxel/carboplatin (PC) versus cisplatin/irinotecan (CPT-P) as first-line chemotherapy in patients with clear cell carcinoma (CCC) of the ovary: A Japanese Gynecologic Oncology Group (JGOG)/GCIG study. (Aikou Okamoto)

5. Abstract #LBA5500 (130933) A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. (Joyce Liu)

6. Abstract #5504 (134878) Progression-free survival in ovarian cancer patients in second remission with mucin-1 autologous dendritic cell therapy. (Heidi J. Gray)

7. Abstract #5502 (133112) Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. (Charlie Gourley)

8. Abstract #10509 (134602) Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities. (Sujana Movva)9.15 – 9.35 Discussion

II. Head&Neck Cancer and Melanoma SessionChairmen: Juraj Beniak, Pavel Dubinský (09.35 – 10.35)

9.35 – 9.55

3. Head&Neck Cancer (Dagmar Sorkovská, OÚSA Bratislava)

1. Abstract # 6001 (128063) Impact of p16 status on the results of the phase III cetuximab (cet)/radiotherapy (RT). (David Ira Rosenthal)
2. Abstract # LBA6006 (133616) E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). (Anthony Cmelak)
3. Abstract # 6004 (129831) Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/ Cisplatin/5- Fluorouracil (TPF) followed by CRT or CET/RT in patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN). A randomized phase III factorial study (NCT01086826). (Maria Grazia Ghi)
4. Abstract # 6005 (131562) Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN). (Kevin J. Harrington)
5. Abstract # LBA6008 (132694) A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I- refractory differentiated thyroid cancer (SELECT). (Martin Schlumberger)09.55 – 10.15

4. Melanoma (Zuzana Hlavatá, NOÚ Bratislava)

1. Abstract # LBA9000^ (133842) Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). (Antoni Ribas)
2. Abstract # LBA9003^ (126008) Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS- 936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). (Mario Sznol)
3. Abstract # S9011^ (128598) COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma. (Georgina V. Long)
4. Abstract # 9002 (125578) Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO- 4538) in a phase I trial. (F. Stephen Hodi)
5. Abstract # 9008 (130118) Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. (Alexander M. Eggermont)10.15 – 10.45 Discussion10.45 – 11.00 Coffee-Break

III. Lung Cancer/Patient and Survivor Care SessionChairmen: Jozef Chovanec, Peter Kasan (11.00 – 12.00)

11.00 – 11.20

5. Lung Cancer (Peter Beržinec, ŠN Sv. Svorada, Nitra)

1. Abstract # 8002 (129938) First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK- positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). (Tony Mok)
2. Abstract # 8003^ (128749) Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. (Dong-Wan Kim)
3. Abstract # 8009^ (129721) Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC). (Pasi A. Janne)
4. Abstract # 8005 (127760) Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation– positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial. (Terufumi Kato)
5. Abstract # 8008^ (125543) A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous nonsmall cell lung cancer (sq-NSCLC). (Nick Thatcher)
6. Abstract # LBA8006^ (126433) REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy. (Maurice Perol)
7. Abstract # 7500 (132928) A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CCheIN). (Keunchil Park)
8. Abstract # 7501 (127366) A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non- small cell lung cancer (NSCLC): RADIANT results. (Karen Kelly)
9. Abstract # 7502 (125440) Randomized trial on thoracic radiotherapy (TRT) in extensivestage small cell lung cancer. (Ben J. Slotman)
10. Abstract # 7503 (129034) Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial. (Takashi Seto)

11.20 – 11.40

6. Patient and Survivor Care (Richard Hrubý, FNsP Žilina)

1. Abstract # LBA9500^ (129791) Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial. (Gabriel N. Hortobagyi)
2. Abstract # 9503 (127891) Aprepitant versus metoclopramide, both combined with dexamethasone, for preventing cisplatin-induced delayed emesis: A randomized, double-blind study. (Fausto Roila)
3. Abstract # 9506 (128852) Increasing cardiovascular screening in at-risk adult survivors of pediatric malignancies: A randomized controlled trial. (Melissa M. Hudson)
4. Abstract # 9507 (125315) Impact of vaginal dehydroepiandosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance). (Debra L. Barton)
5. Abstract # LBA9513 (131678) Benefits of immediate versus delayed palliative care to informal family caregivers of persons with advanced cancer: Outcomes from the ENABLE III randomized clinical trial. (J Nicholas Dionne-Odom)
6. Abstract # LBA9514 (135132) Managing comorbidities in oncology: A multisite randomized controlled trial of continuing versus discontinuing statins in the setting of life-limiting illness. (Amy Pickar Abernethy)

11.40 – 12.00 Discussion

12.00 – 13.30 Lunch

IV. Gastrointestinal Cancer SessionChairmen: Vladimír Malec, Tomáš Šálek (13.30 – 14.30)

13.30 – 13.50

7. Gastrointestinal cancer (Non-Colorectal/GIST) (Štefan Pörsök, NOÚ Bratislava)

8. Abstract # 4000 (128761) A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC). (Herbert Hurwitz)

9. Abstract # 4008 (133331) Phase III trial to compare capecitabine/cisplatin (XP) versus XP plus concurrent capecitabine-radiotherapy in gastric cancer (GC): The final report on the ARTIST trial. (Jeeyun Lee)

10. Abstract # 4003 (125661) Phase III study of apatinib in advanced gastric cancer: A randomized, double-blind, placebo-controlled trial. (Shukui Qin)

11. Abstract # 4005 (132412) RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of metastatic gastroesophageal junction and gastric adenocarcinoma (mGC) following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy – Efficacy analysis in Japanese and Western patients. (Shuichi Hironaka)

12. Abstract # 4006^ (133873) STORM: A phase III randomized, double-blind, placebocontrolled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). (Jordi Bruix)

13. Abstract # 10506 (132546) A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: Initial report. (Michael C. Heinrich)

14. Abstract # 10508 (134128) Long-term disease control of advanced gastrointestinal
    stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033. (George D. Demetri)13.50 – 14.10

15. Gastrointestinal (Colorectal) Cancer (Marián Kakalejčík, POKO Poprad)

16. Abstract # LBA3 (126013) CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). (Alan P. Venook )

17. Abstract #: 3500 (133115) Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and xaliplatin versus 5- fluorouracil alone in locally advanced rectal cancer: Results of the German CAO/ARO/AIO-04 randomized phase III
    trial. (Claus Rodel)

18. Abstract # 3503^ (133066) Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207). (Dirk Arnold )

19. Abstract # 3504 (131325) Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC). (Miriam Koopman)

20. Abstract # 3507 (134364) Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. (Daniel J. Sargent)

14.10 – 14.30 Discussion

14.30 – 14.45 Coffee-Break

V. Breast Cancer SessionChairmen: Mária Wagnerová, Stanislav Špánik (14.45 – 15.45)

14.45 – 15.05

9. Breast Cancer – HER2/ER+ (Mária Višňovská, VOÚ Košice)

1. Abstract # LBA1 (129398) Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG text_html and SOFT trials. (Olivia Pagani)
2. Abstract # LBA4 (128258) First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). (Martine J. Piccart-Gebhart)
3. Abstract # 508 (130769) Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2-positive breast cancer and tumors ≤ 2cm: A meta-analysis of the randomized trastuzumab trials. (Ciara Catherine Maria O’Sullivan)
4. Abstract # 500 (130506) Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast. (Kathy Miller) ID: 504 (128900)
5. Abstract # 504 (128900) Prognostic associations of 25OH vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC). (Ana Elisa Lohman)

15.05 – 15.25

10. Breast Cancer – Triple-Negative/Local Therapy (Radovan Barilla, Onkologická klinika Sveta zdravia, Michalovce)

1. Abstract # 510 (132115) Expression of immunologic genes in triple-negative and HER2- positive breast cancer in the neoadjuvant GEPARSIXTO trial: Prediction of response to carboplatin-based chemotherapy. (Carsten Denkert)
2. Abstract # 1005 (131770) Pathological complete response (pCR) rates after carboplatincontaining neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto. (Gunter Von Minckwitz)
3. Abstract # 1017 (135156) Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer. (Kenji Tamura)
4. Abstract # 1019^ (129202) Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC): Hoosier Oncology Group BRE09-146. (Sujaata Dwadasi)
5. Abstract # 511 (134201) Tracking tumor-specific mutations in circulating-free DNA to predict early relapse after treatment of primary breast cancer. (Nicholas C. Turner)

15.25 – 15.45 Discussion

15.45 – 15.50 Closing remarks
President of Slovak Oncology Society, Jozef Mardiak

FAREWELL

SOLEN, s.r.o.

Ambrova 5,

831 01 Bratislava

tel. 02/5413 1365

fax: 02/ 5465 1384

e-mail: kongres@solen.sk

www.solen.sk

Mgr. Andrej Šutka,  kongres@solen.sk

Ing. Monika Liedlová,  liedlova@solen.sk